Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 14;102(15):e33526.
doi: 10.1097/MD.0000000000033526.

Serum asprosin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome: A retrospective case-control study

Affiliations

Serum asprosin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome: A retrospective case-control study

Ling Zhu et al. Medicine (Baltimore). .

Abstract

Dysregulation of adipokines may play a role in the development of polycystic ovary syndrome (PCOS). This was a retrospective case-control study to investigate the relationship between asprosin and insulin resistance in patients with PCOS patients. The study enrolled 213 PCOS patients and 213 age-matched and body mass index-matched controls. The serum asprosin levels and the relationship between asprosin and PCOS with IR were compared between the 2 groups. In the current study, it was found that the serum asprosin level and hemostasis of model assessment-insulin resistance of PCOS were significantly higher than those of the control group, and asprosin was independently correlated with hemostasis of model assessment-insulin resistance and CRP (P < .05). Asprosin was found to be statistically significant in the analysis of receiver operating characteristics, and the specific result was 0.826 (0.724-0.879). This study emphasizes that increased levels of asprosin are independently associated with PCOS, and asprosin may be a new indicator for evaluating insulin resistance in PCOS patients.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
ROC curves, AUC values and standard error, P value, and 95% CI of the AUC of asprosin. 95% CI = 95% confidence interval, AUC = area under the curves, OR = odds ratio, ROC = receiver operating characteristics, SE = standard error.

Similar articles

Cited by

References

    1. Fauser BC, Tarlatzis BC, Rebar RW, et al. . Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.e25. - PubMed
    1. Polak K, Czyzyk A, Simoncini T, et al. . New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1–8. - PMC - PubMed
    1. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43. - PubMed
    1. Longo M, Zatterale F, Naderi J, et al. . Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019;20:2358. - PMC - PubMed
    1. Farrag M, Ait Eldjoudi D, González-Rodríguez M, et al. . Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol (Lausanne). 2023;13:1101091. - PMC - PubMed